Sign up now and fund within 24h to get free NKE, GPRO or DBX stock. T&Cs apply.
Redeem Now

Rhythm Pharmaceuticals Inc

1 day chart

Created with Highcharts 11.1.0
Kickstart your portfolio with a U.S. stock on us

Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.

Sign up and fund a new Wall St account and get a full U.S. share.

T&Cs apply
Claim now
Kickstart your portfolio with a U.S. stock on us

About RYTM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.

Market Capitalisation

$3.65B

Price-earnings ratio

-

Dividend yield

0.00%

Volume

895.48K

High today

$62.28

Low today

$57.28

Open price

$60.73

52-week high

$68.58

52-week low

$35.17

Ready to start your investing journey with Stake?

Open an account

RYTM FAQs

Buying RYTM shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Rhythm Pharmaceuticals Inc in minutes.
  1. Sign up with some I.D. and zero paperwork
  2. Add funds to your account
  3. Make your first investment in RYTM

The ticker symbol for Rhythm Pharmaceuticals Inc is RYTM.

One share of RYTM is valued at $57.50 as of 10 May 2025.

As of 10 May 2025 Rhythm Pharmaceuticals Inc has a market cap of $3.65B.

The Rhythm Pharmaceuticals Inc 52-week high stock price is $68.58.

The Rhythm Pharmaceuticals Inc 52-week low stock price is $35.17.

Yes, the Stake investing platform allows you to buy RYTM shares and over 9,500 more stocks and ETFs on Wall St.

This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in RYTM
on Stake

Buy RYTM from US$3 brokerage

Invest in 9,500+ U.S. stocks and ETFs

Own a slice of RYTM from only US$10 with fractional shares

Get started
Stake app chart
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.
RYTM related stocks

Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd is registered as an overseas company in New Zealand (NZBN: 9429047452152), and is registered as a Financial Service Provider under the Financial Service Providers (Registration and Dispute Resolution) Act 2008 (No. FSP774414). We hold a full licence issued by the Financial Markets Authority to provide a financial advice service under the Financial Markets Conduct Act 2013. However, the content on this website has not been prepared to take into account any of your individual objectives, financial situation or needs. To the extent you require further information about the relevant New Zealand legislation that may apply, or require specific advice, please contact your legal and/or financial adviser (as appropriate). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Terms & Conditions, Privacy Policy, Financial Advice Disclosure and Disclaimers before deciding to use or invest on Stake. By using the Stake website or service in any way, you agree to our Privacy Policy and Terms & Conditions All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake is a registered trademark under class 36 (New Zealand).

Copyright © 2025 Stake. All rights reserved.